专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

EP1638492B1 PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN 失效转让
标题翻译：术后疼痛前处理
公开(公告)号：EP1638492B1
公开(公告)日：2008-01-02
申请号：EP04779185.0
申请日：2004-07-26
申请人： Euro-Celtique S.A.
发明人： REIDENBERG, Bruce, E. , SPYKER, Daniel, A.
IPC分类号： A61K31/485 , A61K9/70
CPC分类号： A61K9/0014 , A61K9/7023 , A61K31/485
摘要： A method of treating postoperative pain in a patient undergoing a surgery id described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain.

62. 发明公开

EP1795189A3 Method of administering buprenorphine to treat depression 审中-公开
标题翻译：抑郁症的治疗给药丁丙诺啡方法
公开(公告)号：EP1795189A3
公开(公告)日：2007-08-15
申请号：EP07007006.5
申请日：2003-03-20
申请人： EURO-CELTIQUE S.A.
发明人： Kaiko, Robert F. , Sanchez, Ramiro
IPC分类号： A61K9/70 , A61K31/485 , A61P25/24
CPC分类号： A61K9/7023 , A61K31/485
摘要： A method of treating depression using transdermal delivery of buprenorphine is described. In one embodiment, the method employs transdermal patches comprising buprenorphine, preferably escalating incrementally the buprenorphine dose to a level where one or more symptoms of depression are alleviated. The method is particularly suitable for r patients suffering from refractory depression, or for patients suffering from both depression and pain.

63. 发明授权

EP1631285B1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN 无效
标题翻译：疼痛合适的治疗剂的治疗
公开(公告)号：EP1631285B1
公开(公告)日：2007-08-08
申请号：EP04776652.2
申请日：2004-06-14
申请人： Euro-Celtique S.A.
发明人： KYLE, Donald, J. , SUN, Qun , TAFESSE, Laykea
IPC分类号： A61K31/44 , A61K31/495 , C07D213/02 , C07D401/02 , A61P25/00
CPC分类号： C07D211/78 , C07D213/02 , C07D401/02 , C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/04 , C07D417/14
摘要： A compound of formula: wherein Ar1, Ar2, V, X, R3, R4, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a 'Cyclo(hetero)alkenyl Compound'); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

64. 发明公开

EP1810970A1 Therapeutic piperazine compounds 有权
标题翻译：治疗Piperazinverbindungen
公开(公告)号：EP1810970A1
公开(公告)日：2007-07-25
申请号：EP07104074.5
申请日：2003-09-24
申请人： EURO-CELTIQUE S.A.
发明人： Sun, Qun , Zhou, Xiaoming
IPC分类号： C07D403/04 , C07D401/04 , C07D285/10 , C07D237/20 , C07D241/20 , C07D239/42 , C07D213/74 , A61K31/496 , A61P29/00
CPC分类号： C07D401/04 , C07D403/04 , C07D417/04
摘要： The present invention relates to Hydroxyiminopiperazine Compounds for use and treating or preventing a condition treatable or preventable by inhibiting VR 1 , and compositions comprising an effective amount of Hydroxyiminopiperzine Compound.
摘要翻译：本发明涉及用于和治疗或预防通过抑制VR 1可治疗或可预防的病症的羟基亚氨基哌嗪化合物和包含有效量的羟基亚氨基哌嗪化合物的组合物。

65. 发明公开

EP1786404A2 OPIOID DOSAGE FORMS HAVING DOSE PROPORTIONAL STEADY STATE CAVE AND AUC AND LESS THAN DOSE PROPORTIONAL SINGLE DOSE CMAX 审中-公开
标题翻译：阿片类剂型剂量定PI和AUC的稳态洞穴尚能CMAX LESS THAN成正比剂量
公开(公告)号：EP1786404A2
公开(公告)日：2007-05-23
申请号：EP05793064.6
申请日：2005-08-30
申请人： EURO-CELTIQUE S.A.
发明人： WRIGHT, Curtis , COLUCCI, Robert , EL-TAHTAWY, Ahmed
IPC分类号： A61K9/22 , A61K9/30 , A61K9/52 , A61K31/485
CPC分类号： A61K31/194 , A61K9/1629 , A61K9/1635 , A61K9/1658 , A61K9/2077 , A61K31/485
摘要： The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.

66. 发明公开

EP1765349A1 OPIOIDS FOR THE TREATMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 失效转让
标题翻译：用于治疗慢性阻塞性肺病于治疗阿片类药物（COPD）
公开(公告)号：EP1765349A1
公开(公告)日：2007-03-28
申请号：EP05756456.9
申请日：2005-06-08
申请人： EURO-CELTIQUE S.A.
发明人： FLEISCHER, Wolfgang , REIMER, Karen , LEYENDECKER, Petra
IPC分类号： A61K31/485 , A61P11/00
CPC分类号： A61K31/485 , A61K2300/00
摘要： The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).

67. 发明公开

EP1718258A2 ABUSE RESISTANT OPIOID TRANSDERMAL DELIVERY DEVICE CONTAINING OPIOID ANTAGONIST MICROSPHERES 有权转让
标题翻译： MISSBRAUCHSICHERE TRANSDERMALE ABGABEVORRICHTUNGFÜROPIOIDE，FORTHALTEND OPIOIDANTAGONIST FOR FORM VONMIKROKÜGELCHEN
公开(公告)号：EP1718258A2
公开(公告)日：2006-11-08
申请号：EP05713575.8
申请日：2005-02-15
申请人： EURO-CELTIQUE S.A.
发明人： REIDENBERG, Bruce , SHEVCHUK, Ihor , TAVARES, Lino , LONG, Kevin , MASKIEWICZ, Richard , SHAMEEM, Mohammed
IPC分类号： A61F13/00
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/1611 , A61K9/1647 , A61K9/703 , A61K9/7061 , A61K9/7092 , B09B3/0075 , B09B2220/14
摘要： The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.
摘要翻译：本发明提供了在疼痛患者中含有用于止痛目的的阿片样物质激动剂的耐药性透皮递送装置。

68. 发明公开

EP1709029A2 METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS 审中-公开
标题翻译：制备4-四唑-4-基苯基哌啶化合物的方法
公开(公告)号：EP1709029A2
公开(公告)日：2006-10-11
申请号：EP05712568.4
申请日：2005-01-31
申请人： EURO-CELTIQUE S.A.
发明人： BROWN, Kevin , DOYLE, Timothy, J. , WHITEHEAD, John, W.,F.
IPC分类号： C07D401/04 , C07D211/64 , C07D257/04 , C07D307/22 , C07C237/20
CPC分类号： C07D211/64 , C07D257/04 , C07D307/22 , C07D401/04
摘要： Methods, composition, and intermediates are disclosed that are useful for making 4-Tetrazolyl-4-phenylpiperidine Compounds according to Formula (I), where Ar1 is -C3-C8 cycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Ar2 is phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Z1 and Z2 are each independently a -(C1-C4 alkyl) group; R1 is -(CH2)nC(O)N(R3)(R4) where R3 and R4 are each independently H or -(C1-C4 alkyl); R2 is halogen, -C1-C3 alkyl, -O-(C1-C3 alkyl), -NH(C1-C3 alkyl) or -N(C1-C3 alkyl)2; n is an integer ranging from 1 to 4; m is an integer ranging from 0 to 4; and, in certain embodiments, the phenyl moiety attached to the 4-position of the piperidine ring of a compound according to Formula (I) can be optionally substituted with one or mor R2 groups.
摘要翻译：公开了用于制备式（I）的4-四唑基-4-苯基哌啶化合物的方法，组合物和中间体，其中Ar1是-C3-C8环烷基，苯基，萘基，蒽基，菲基或 - （5-7 - 元）杂芳基，各自未被取代或被一个或多个R 2基团取代; Ar 2是苯基，萘基，蒽基，菲基或 - （5-7元）杂芳基，各自未被取代或被一个或多个R 2基团取代; Z 1和Z 2各自独立地为 - （C 1 -C 4烷基）基团; R 1是 - （CH 2）n C（O）N（R 3）（R 4），其中R 3和R 4各自独立地为H或 - （C 1 -C 4烷基）。 R2为卤素，-C1-C3烷基，-O-（C1-C3烷基）， - NH（C1-C3烷基）或-N（C1-C3烷基）2; n是1至4的整数; m是0至4的整数; 并且在某些实施方案中，连接到式（I）化合物的哌啶环的4-位的苯基部分可以任选地被一个或多个R 2基团取代。

69. 发明公开

EP1685839A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist 有权
标题翻译：口服含有阿片样物质激动剂的组合和阿片样物质拮抗剂给药的剂型
公开(公告)号：EP1685839A1
公开(公告)日：2006-08-02
申请号：EP06111805.5
申请日：1998-12-22
申请人： EURO-CELTIQUE S.A.
发明人： Kaiko, Robert F. , Colucci, Robert D.
IPC分类号： A61K31/485 , A61P25/36
CPC分类号： A61K31/485 , A61K31/16 , A61K31/60 , A61K45/06 , Y10S514/81 , Y10S514/812 , A61K2300/00
摘要： The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
摘要翻译：本发明涉及部分地口服剂型包含口服止痛有效量的口服活性阿片样物质拮抗剂的阿片样激动剂和的组合，所述阿片样物质拮抗剂被包括在比所述阿片类激动剂是提供一种组合产品，所有这一切是止痛当有效的组合是口服给药的，但在物理上依赖受试者的所有这是厌恶。优选地，阿片样物质拮抗剂的包含在组合产物的量至少提供一个轻微负，“厌恶”在身体依赖性成瘾经验（E. G.沉淀戒断综合症）。

70. 发明公开

EP1648880A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN 有权
标题翻译：治疗疼痛的治疗药物
公开(公告)号：EP1648880A1
公开(公告)日：2006-04-26
申请号：EP04779721.2
申请日：2004-07-30
申请人： Euro-Celtique S.A.
发明人： KYLE, Donald, J. , SUN, Qun
IPC分类号： C07D401/04 , A61K31/495 , A61P1/04 , A61P13/02
CPC分类号： C07D401/04 , C07D213/74 , C07D213/85
摘要： Compounds of formulae (I) and (II) where X is S or O and Ar2, R1, R2, R3, R8, n, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a '3-substituted Pyridyl Compound'), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a 3-substituted Pyridyl Compound are disclosed herein.
摘要翻译：其中X是S或O和Ar 2，R 1，R 2，R 3，R 8，n，m和t的式（I）和（II）化合物或其药学上可接受的盐（'3-取代的吡啶基化合物'），包含有效量的3-取代的吡啶基化合物的组合物，以及用于治疗或预防疼痛，尿失禁，溃疡，炎性肠病，肠易激综合征，成瘾症，帕金森病，帕金森病，焦虑症，癫痫症，中风，惊厥，瘙痒症状，精神病，认知障碍，记忆缺陷，脑功能受限，亨廷顿舞蹈症，肌萎缩侧索硬化症，痴呆，视网膜病，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症在动物中给予有需要的动物有效量的本发明公开的3-取代的吡啶基化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式